Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been assigned a consensus rating of “Buy” from the sixteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $48.9167.

Several analysts recently commented on SRRK shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Wolfe Research assumed coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective for the company. Barclays raised their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Finally, HC Wainwright cut their price objective on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total value of $44,354.54. Following the completion of the sale, the director owned 32,908 shares of the company’s stock, valued at approximately $1,450,913.72. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mo Qatanani sold 136,462 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the transaction, the insider owned 108,964 shares in the company, valued at approximately $4,926,262.44. The trade was a 55.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 13.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the business. Ramirez Asset Management Inc. acquired a new position in Scholar Rock during the 3rd quarter valued at about $37,000. Penserra Capital Management LLC bought a new position in shares of Scholar Rock in the third quarter valued at approximately $56,000. Strs Ohio purchased a new position in shares of Scholar Rock during the first quarter valued at approximately $77,000. Bessemer Group Inc. grew its holdings in Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock worth $86,000 after buying an additional 2,105 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in Scholar Rock during the second quarter worth $94,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Scholar Rock stock opened at $41.31 on Wednesday. The stock has a fifty day moving average of $39.90 and a 200-day moving average of $36.45. The stock has a market capitalization of $4.21 billion, a P/E ratio of -13.11 and a beta of 0.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. Scholar Rock has a 52 week low of $22.71 and a 52 week high of $48.28.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the company posted ($0.66) earnings per share. On average, sell-side analysts expect that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).